Transactions
2
Insider / Xilio Therapeutics, Inc.
Shannon James Samuel
Director at Xilio Therapeutics, Inc.
- Company
- Xilio Therapeutics, Inc.
- Ticker
- XLO
- First filing on record
- March 30, 2026
- Latest trade on record
- June 11, 2026
- SEC filings
- EDGAR ↗
Shannon James Samuel, Director at Xilio Therapeutics, Inc., has disclosed 2 transactions in XLO since March 30, 2026: 1 purchase (1 open-market buy) and 0 sales, worth about $44K at the reported prices. The latest was filed June 12, 2026, 1 day after the trade.
Open-market buys
1
Sales
0
Avg. disclosure lag
2.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Shannon James Samuel made 1 purchase worth $44K and no sales, plus 1 other transaction. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Shannon James Samuel has traded 1 stock on record; the largest by dollars is XLO.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 1 | 5,000 | — |
| P | Open-market purchase | 1 | 5,000 | $44K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 1 · $44K | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Buy P | March 26, 2026 | March 30, 2026 | 4d | 5,000 | $9 | $44K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| June 12, 2026 | Form 4 | 0001193125-26-269400 | 1 | published | EDGAR ↗ |
| March 30, 2026 | Form 4 | 0001193125-26-131745 | 1 | published | EDGAR ↗ |
Other insiders at Xilio Therapeutics, Inc.
- Frankenfield Christopher James Chief Financial Officer 21 rows
- Russo Rene PRESIDENT AND CEO 20 rows
- Luptakova Katarina CHIEF MEDICAL OFFICER 14 rows
- Brennan Kevin M. SVP, FINANCE AND ACCOUNTING 11 rows
- Bonstein Sara Chief Financial Officer 10 rows
- GILEAD SCIENCES, INC. Insider 7 rows
- Bello Akintunde Olatokumbo Director 1 row
- Blanchard Cheryl R Director 1 row
- Brennan Aoife Director 1 row
- Curran Daniel J. Director 1 row
Everyone on file, with contracts and lobbying under the company's name: Xilio Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | March 30, 2026 | June 12, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.